Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212633 | 0.80 | MLYCD (0.49) | RXFP1MLYCDMEN1KMT2ANPC1 | |
| SCHEMBL1275272 | 0.79 | MLYCD (0.45) | RXFP1MLYCDMEN1KMT2ANPC1 | |
| SCHEMBL3205565 | 0.79 | LMNA (0.36) | MAPK14KMT2ANPC1RAB9ALCK | |
| SCHEMBL29409944 | 0.77 | RXFP1 (0.54) | RXFP1MLYCDMEN1KMT2ANR1H4 | |
| SCHEMBL3211745 | 0.77 | JAK2 (0.40) | RXFP1MEN1KMT2ALCKBTK | |
| SCHEMBL13456091 | 0.77 | RXFP1 (0.43) | RXFP1MLYCDMAPK14MEN1KMT2A | |
| SCHEMBL3211432 | 0.76 | JAK2 (0.49) | RXFP1MAPTJAK2JAK1 | |
| SCHEMBL3227043 | 0.74 | MLYCD (0.48) | RXFP1MLYCDLMNA | |
| SCHEMBL3150926 | 0.74 | RXFP1 (0.54) | RXFP1MLYCDMAPK14MEN1KMT2A | |
| SCHEMBL3222728 | 0.74 | RXFP1 (0.41) | RXFP1MLYCDMAPK14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184343-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION LLC (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013092942-A1 | USE OF AMINOBENZAMIDE DERIVATIVES FOR CONTROLLING ANIMAL PARASITES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-8420855-B2 | Insecticidal compounds | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420855-B2 | Insecticidal compounds | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100048715-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048715-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2008000438-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048715-A1 | INSECTICIDAL COMPOUNDS | ACHE, CHRM1, CHRM2 | RXFP1 1992/4885MLYCD 3539/4885MAPK14 4661/4885 |
| US-20130184343-A1 | INSECTICIDAL COMPOUNDS | ACHE, CHRM1, CHRM2 | RXFP1 2047/4885MLYCD 3515/4885MAPK14 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.